Quick Takeaways
- Deep Track Capital, LP filed SCHEDULE 13G for PROTAGONIST THERAPEUTICS, INC. Common Stock, par value $0.00001 (PTGX).
- Disclosed ownership: 5.3%.
- Date of event: 03 Apr 2025.
Deep Track Capital, LP - 03 Apr 2025 SCHEDULE 13G Report for PROTAGONIST THERAPEUTICS, INC. Common Stock, par value $0.00001 (PTGX)
- Filing Manager
- Deep Track Capital, LP
- Reporting Manager
- Deep Track Capital, LP
- Symbol
- PTGX
- Shares outstanding
- 61,436,673 shares
- Disclosed Ownership
- 3,250,000 shares
- Ownership
- 5.3%
- Form type
- SCHEDULE 13G
- Filing time
- 10 Apr 2025, 16:14:54 UTC
- Date of event
- 03 Apr 2025
- Next filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Deep Track Capital, LP disclosed 5.3% ownership in PROTAGONIST THERAPEUTICS, INC. Common Stock, par value $0.00001 (PTGX) on 03 Apr 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 10 Apr 2025, 16:14.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 5.3% | 3,250,000 | 0 | 3,250,000 | /s/ David Kroin | David Kroin, Managing Member of the General Partner of the Investment Adviser | |
| Deep Track Biotechnology Master Fund, Ltd. | 5.3% | 3,250,000 | 0 | 3,250,000 | /s/ David Kroin | David Kroin, Director | |
| David Kroin | 5.3% | 3,250,000 | 0 | 3,250,000 | /s/ David Kroin | David Kroin |